Brady Stephen R 4
4 · Tempest Therapeutics, Inc. · Filed Jan 6, 2022
Insider Transaction Report
Form 4
Brady Stephen R
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2022-01-04+94,500→ 94,500 totalExercise: $5.45Exp: 2032-01-03→ Common Stock (94,500 underlying)
Footnotes (1)
- [F1]These stock options vest in a series of 48 equal monthly installments measured from January 4, 2022, subject to the reporting person's continued service.